July 2025

28 Jul Pluristyx Completes Investment Round to Expand Product Portfolio and Commercial Operations

We’re pleased to share that Pluristyx, a BroadOak Capital Partners portfolio company, has recently completed an investment round to expand inventory with new clinical grade cell lines. This strategic investment will enable Pluristyx to be the industry leader offering the highest quality stem cells available...